Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.8713 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.8713 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.8713 | 1 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.8713 | 1 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.8713 | 1 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.8713 | 1 | 1 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.8713 | 1 | 0.5 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.3531 | 0 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.8713 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IZ (functional) | = 14.5 mm | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hr by disk diffusion method | ChEMBL. | No reference |
IZ (functional) | = 23.7 mm | Antifungal activity against Candida albicans by disk diffusion method | ChEMBL. | No reference |
MBC (functional) | > 100 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hr followed by subculturing measured after 18 to 24 hr | ChEMBL. | No reference |
MFC (functional) | = 50 ug ml-1 | Antifungal activity against Candida albicans incubated for 48 hr followed by subculturing measured after 48 hr | ChEMBL. | No reference |
MIC (functional) | = 25 ug ml-1 | Antifungal activity against Candida albicans after 48 hr | ChEMBL. | No reference |
MIC (functional) | = 50 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hr by broth dilution method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.